Idevax, Rabian, and Artemis Bioservices Join Forces in EUROSTARS Project RABIVA
Antwerp, Belgium – October 1, 2025 – Idevax, Rabian, and Artemis Bioservices are proud to announce their collaboration on the EUROSTARS-funded project RABIVA, an ambitious initiative aimed at transforming the prevention and management of RNA virus outbreaks through innovative, accessible solutions.
RABIVA (World’s first accessible, inexpensive approach for RABies Intradermal VAccination) will focus initially on rabies—a 100% vaccine-preventable disease that still causes over 60,000 deaths annually. The project integrates cutting-edge technologies to develop a cost-effective, scalable, and user-friendly vaccination platform suitable for both endemic regions and travelers.
The project has received funding from the EUROSTARS programme, part of the European Commission’s Horizon Europe initiative, with support from VLAIO (Flanders) and RVO (The Netherlands).
Vanessa Vankerckhoven, CEO & Founder of Idevax, shared: “We’re thrilled to collaborate with Rabian and Artemis Biosciences on RABIVA. Idevax will lead the development of RAB-ID, a high-precision intradermal vaccination device based on our CE-marked VAX-ID® technology.”
Koen Beyers, Founder & CTO of Idevax added: “This device enables accurate, low-dose administration, making vaccination more efficient and accessible. We’re honored to receive support from EUROSTARS and VLAIO for this important work.”
Carine Punt, CEO & Founder of Rabian, added: “Our novel rabies vaccine, based on Dyadic’s C1 production platform, offers high immunogenicity and represents a major leap forward in vaccine development, production and innovation.”
Byron Martina, CEO & Founder of Artemis Bioservices, stated: “We will provide preclinical proof-of-concept in two models and guide the VAX-C1 vaccine candidate toward cGMP production and Phase 1/2 clinical trials following the project.”
Prof. Ab Osterhaus, Scientific Advisor to the RABIVA project, commented: “Rabies remains an invariably lethal, yet entirely preventable disease. By combining next-generation vaccine technology with precision delivery systems, RABIVA has the potential to set a new standard in tackling rabies, as an example for remaining viral threats. This shows how scientific progress can directly serve global health.”
Together, the RABIVA consortium aims to deliver a game-changing rabies vaccination solution by combining two validated platforms: Rabian’s next-generation vaccine and Idevax’s precision delivery device. VAX-ID will be able to show case its potential of accurate and consistent delivery, low pain perception and high ease of use. This integrated approach has the potential to significantly reduce the global burden of rabies and pave the way for broader RNA-virus preparedness.
Contact:
Vanessa Vankerckhoven – Founder & CEO –Vanessa.vankerckhoven@idevax.com – +32486761885
About Idevax
Idevax is a pioneering medical device company based in Antwerp and Wijnegem, Flanders, Belgium. Founded in 2020 by Vanessa Vankerckhoven and Koen Beyers, Idevax is an ISO13485-certified company dedicated to developing, producing, and commercializing innovative precision drug delivery devices. The company’s mission is to enable reliable skin drug delivery and enhance patient comfort through cutting-edge solutions and commitment to excellence. The VAX-ID device platform has CE mark to deliver medications and vaccines intradermally. The devices are safe, accurate, easy to use by healthcare professionals and offer patient comfort. They can improve vaccine effectiveness and offer dose-sparing potential. For more information or if you are interested in partnering with us, check out our website or contact us. Follow us on LinkedIn.
About Rabian
Rabian BV is an innovative Dutch SME in the field of infectious diseases, founded in 2023 by a multi-disciplinary team of seasoned entrepreneurs and world-leading scientists with a broad background in immunology, virology and commercialization. It is our mission to develop cost-effective vaccines and post-exposure treatments of diseases with endemic and pandemic potential. We aim to become a leading developer of cost-effective vaccine and prophylactic therapies of endemic infectious diseases, with a first proof of C1-platform produced rabies vaccine. For more information, please contact us via our website.
About Artemis Bioservices
Artemis Bioservices is an organization specialized in the early-stage evaluation of viral vaccines and antiviral therapeutics, in particular against emerging, zoonotic and vector-borne diseases. For more information, see our website
